- Commissioner’s statement on Ventura, Marte
- Ronnie O’Sullivan: Masters champion ‘felt so vulnerable’ in final
- Arron Fletcher Wins 2017 WSOP International Circuit Marrakech Main Event ($140,224)
- Smith challenges Warner to go big in India
- Moncada No. 1 on MLB Pipeline’s Top 10 2B Prospects list
- Braves land 2 on MLB Pipeline’s Top 10 2B Prospects list
- Kingery makes MLB Pipeline’s Top 10 2B Prospects list
- New Zealand wrap up 2-0 after Bangladesh implosion
- Mathews, Pradeep, Gunathilaka to return to Sri Lanka
- Elliott hopes for rain for Poli
How does Byrd’s suspension impact Indians?
- Updated: June 1, 2016
CLEVELAND — The Indians’ outfield has been dealing with setbacks since the offseason. On Wednesday, that segment of Cleveland’s roster was dealt another blow with the news that veteran Marlon Byrd has received a 162-game suspension for testing positive for a performance-enhancing substance.
Byrd tested positive for the growth hormone secretagogue Ipamorelin, which violates Major League Baseball’s Joint Drug and Prevention Program. It is the second suspension of Byrd’s career, and the second this season for an Indians outfielder, following Abraham Almonte’s 80-game punishment during Spring Training for testing positive for Boldenone.
• Byrd gets 162-game suspension for PEDs
“It’s disappointing,” said Chris Antonetti, the Indians’ president of baseball operations. “But our responsibility now is to deal with that reality and give other guys opportunities to contribute and step forward, and contribute and pick up the slack with it.”
Beyond the suspensions, Cleveland’s outfield corps has also been hit with injuries this season. Left fielder Michael Brantley underwent surgery on his right shoulder in November and is currently on the 15-day disabled list for the second time this season. Right fielder Lonnie Chisenhall, while healthy and back with the Tribe, missed most of the spring and a portion of April due to wrist and forearm problems.
Here is a look at how the latest setback affects the Indians’ …
continue reading in source mlb.mlb.com
